News

Sorted by: Date | Title

Drug shortage linked to greater risk of relapse in young Hodgkin lymphoma patients

December 26, 2012
A national drug shortage has been linked to a higher rate of relapse among children, teenagers and young adults with Hodgkin lymphoma enrolled in a national clinical trial, according to a report by researchers involved in the multi-institutional study.

Potential gene therapy approach to sickle cell disease highlighted at ASH

December 11, 2012
Proof-of-concept animal study selected as one of the best presentations at 54th American Society of Hematology Annual Meeting and Exposition

Intensified chemotherapy shows promise for children with very high-risk form of leukemia

December 10, 2012
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber Boston Children's Cancer and Blood Disorders Center in Boston.

The American Society of Hematology Elects New Leadership

October 04, 2012
The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of four new members to its Executive Committee, the governing body of the organization, for terms to begin in January 2013.

Dana-Farber/Children's Hospital Cancer Center establishes training program with Egypt Cancer Network and Children's Cancer Hospital Egypt

September 21, 2012
Egypt-based program for physicians from Egypt, the Middle East and North Africa Dana-Farber/Children's Hospital Cancer Center is announcing a partnership with the Egypt Cancer Network and Children's Cancer Hospital Egypt in an effort to improve childhood cancer survival rates and outcomes within Egypt, the Middle East and North Africa. The organizations are collaborating to create an Egypt-based fellowship training program in pediatric oncology for physicians in those regions.

Key mutations discovered for most common childhood brain cancer

July 23, 2012
Findings could enable individualized treatment for patients with medulloblastoma Researchers at Dana-Farber Boston Children's Cancer and Blood Disorders Center and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

American Association for Cancer Research honors D'Andrea

April 06, 2012
The American Association for Cancer Research presented Alan D. D'Andrea, MD, the Alvan T. and Viola D. Fuller American Cancer Society professor of radiation oncology at the Dana-Farber Cancer Institute and Harvard Medical School, with the 52nd Annual AACR G.H.A. Clowes Memorial Award for his work in understanding cancer survival and progression, which has included milestones such as cloning the erythropoietin receptor and discovering the Fanconi anemia family of proteins involved in maintaining DNA stability.

Justin Bieber Dream Date Shines Light on Rare Pediatric Cancer

February 14, 2012
Avalanna Routh celebrated Valentine's Day this year with a date for the ages. The six-year-old Dana-Farber Boston Children's Cancer and Blood Disorders Center patient, who has been diagnosed with a rare brain tumor, went on a "dream date" with Justin Bieber, thanks in part to a Facebook campaign to have Routh meet the pop star. As important as the date itself, however, is the attention it has focused on atypical teratoid rhabdoid tumor, or AT/RT.

Williams honored for Outstanding Achievement by ASGCT

January 23, 2012
Congratulations to David Williams, MD, chief of the Division of Hematology/Oncology and director of Translational Research at Children's, and associate chair of Pediatric Oncology at Dana-Farber Cancer Institute, who has been selected by the American Society of Gene & Cell Therapy as the recipient of their 2012 Outstanding Achievement Award.
Showing 1-9 of 9 items